Exploratory endpoints
To evaluate ctDNA dynamics as a measure of camonsertib anti-tumor activity, ctDNA samples collected at baseline (88%; 106/120 patients) and longitudinally (83%; 100/120 patients) were subjected to targeted sequencing using a commercially available 105-gene liquid biopsy test. In the efficacy-evaluable population, 64% (63/99) had sufficient ctDNA levels for analysis, both at baseline and on treatment (